Astrana reported FY 2025 total revenue of USD 3.2 billion, up 56%, with adjusted EBITDA of USD 205.4 million (up 21%) and free cash flow of USD 104.5 million. Net income attributable to shareholders was USD 22.5 million, with diluted EPS of USD 0.46 and adjusted diluted EPS of USD 2.20. For Q4 2025, Astrana posted total revenue of USD 950.5 million, up 43%, and adjusted EBITDA of USD 52.5 million, up 50%. Net income attributable to shareholders was USD 6.0 million, with diluted EPS of USD 0.12 and adjusted diluted EPS of USD 0.54. The company said Prospect Health integration is ahead of schedule and issued 2026 guidance for total revenue of USD 3.8 billion to USD 4.1 billion and adjusted EBITDA of USD 250 million to USD 280 million. Astrana also said it will file a Form 12b-25 to extend the deadline for its FY 2025 Form 10-K, citing an expected material weakness in internal controls related to acquisition and purchase accounting processes, and noted it does not reflect a material misstatement or require restatements. The board increased the share repurchase authorization to USD 100 million from USD 50 million; Astrana repurchased 633,844 shares in Q4, with USD 35.9 million remaining as of December 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Astrana Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603020700PR_NEWS_USPR_____LA98809) on March 02, 2026, and is solely responsible for the information contained therein.